Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.54 |
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450647 | 0.96 | F10 (0.52) | F10F2CCR1NR3C1EPHX2 | |
| SCHEMBL3450333 | 0.96 | F10 (0.49) | F10F2CCR1NR3C1EPHX2 | |
| SCHEMBL13108415 | 0.94 | F10 (0.52) | F10F2CCR1NR3C1EPHX2 | |
| SCHEMBL3448288 | 0.94 | F10 (0.50) | F10F2CCR1NR3C1EPHX2 | |
| SCHEMBL3450729 | 0.94 | F10 (0.50) | F10F2CCR1NR3C1EPHX2 | |
| SCHEMBL3450542 | 0.93 | F10 (0.51) | F10F2CCR1NR3C1 | |
| SCHEMBL3448703 | 0.93 | F10 (0.53) | F10F2CCR1NR3C1 | |
| SCHEMBL3451088 | 0.92 | F10 (0.52) | F10F2CCR1NR3C1EPHX2 | |
| SCHEMBL3447605 | 0.92 | F10 (0.50) | F10F2CCR1NR3C1EPHX2 | |
| SCHEMBL13123317 | 0.92 | F10 (0.46) | F10F2CCR1NR3C1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | F10 22/4885F2 1/4885CCR1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.